The purpose of this research was to develop cubosomal mucoadhesive nasal gel to enhance the donepezil HCl delivery to the brain. Glycerol mono-oleate (GMO) and surfactant poloxamer 407 were used to prepare cubosomes. The developed formulations were characterized for particle size (PS), poly dispersity index (PDI), zeta potential (ZP), entrapment efficiency (EE), transmission electron microscopy (TEM), drug release and bio-distribution study in blood and brain tissue. Central composite design was used for the optimization purpose and the selected formulation (containing GMO 2 g and poloxamer 1.5%) was prepared in presence of gellan gum and konjac gum as gelling agent and mucoadhesive agent respectively. The optimal cubosomal dispersion and optimal cubosomal mucoadhesive in situ nasal gel were subjected to bio-distribution studies in rat model. It showed significantly higher transnasal permeation and better distribution to the brain, when compared to the drug solution. Thus, the formulated cubosomal mucoadhesive gel could be considered as a promising carrier for brain targeting of CNS acting drugs through the transnasal route.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/08982104.2018.1552703 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Prospective Clinical Trial Evaluating the Efficacy and Safety of Non-Animal Stabilized Hyaluronic Acid Injections for Non-Surgical Rhinoplasty.
Plast Surg (Oakv)
February 2025
Department of Clinical Anatomy, Mayo Clinic College of Medicine and Science, Rochester, MN, USA.
Non-surgical rhinoplasty with hyaluronic acid (HA) filler is a three-dimensional reshaping technique that achieves tissue enhancement by placing HA deep to nasal skin. Due to its unique rheology, Restylane® Lyft (HA-L, Galderma, Uppsala, Sweden) may be particularly well-suited for injection rhinoplasty, as it has high gel firmness (G') for strong structural support with minimal integration propensity. A prospective clinical trial was conducted to evaluate HA-L use for non-surgical rhinoplasty.
View Article and Find Full Text PDFMight Topical Heparin Help With Occlusion Emergencies After Accidental Intra-Arterial Hyaluronic Acid Injections?
Aesthet Surg J Open Forum
December 2024
Hyaluronic acid fillers rarely cause potentially devastating occlusive adverse events that require immediate hyaluronidase salvage infiltrations. An exploratory photographic investigation probed whether topical heparin's anticlotting and anti-inflammatory properties could synergize with and enhance the effectiveness of hyaluronidase. Based on heparin pharmacodynamics, the authors explored the rationale for associating topical heparins with hyaluronidase in treating occlusive side effects following accidental intra-arterial hyaluronic acid injections.
View Article and Find Full Text PDFDevelopment of a nasal spray based on cyclodextrin/hydrophobically-modified hydroxypropyl-methyl cellulose for the prevention of viral respiratory infections.
Int J Biol Macromol
January 2025
Department of Drug Sciences, University of Pavia, Via Taramelli 12, 27100 Pavia, Italy. Electronic address:
The work aims to develop mucoadhesive and thermo-responsive in situ gelling systems, using hydrophobically-modified hydroxypropyl-methyl cellulose (Sangelose, SG) and beta-cyclodextrin (β-CD) derivatives, for preventing viral respiratory infections. Eight SG/CD systems with varying CD concentrations were evaluated for rheological properties, mucoadhesiveness, spreadability and sprayability via nasal devices; cytotoxicity was in vitro investigated on reconstituted nasal epithelia. Additionally, droplet size distribution and spray deposition were assessed for the most promising systems.
View Article and Find Full Text PDFNanosystems for Intranasal Delivery of Therapeutics in Psychiatric Disorders.
Curr Drug Deliv
January 2025
Neurosciences Research Center (NSRC), Tabriz University of Medical Sciences, Tabriz, Iran.
Due to the blood-brain barrier (BBB) and issues with oral and other traditional routes of administration, psychiatric disorders present significant challenges in getting therapeutics into the brain. The nose-to-brain pathway, also known as intranasal delivery, has shown promise in overcoming these barriers since it targets the brain directly and bypasses the BBB. This review explores nanocarriers' potential for intranasal delivery of therapeutics in the treatment of psychiatric disorders.
View Article and Find Full Text PDFMUC5B regulates alterations in the immune microenvironment in nasopharyngeal carcinoma via the Wnt/β-catenin signaling pathway.
Discov Oncol
January 2025
Department of Ear, Nose and Throat (ENT), The First People's Hospital of Jiande, No. 599 Yanzhou Avenue, Xin'anjiang Street, Jiande, 311600, Zhejiang, China.
Objective: To screen potential differentially expressed genes related to immune function in nasopharyngeal carcinoma through an online database, and to verify their mechanism of action, so as to provide a reference for the diagnosis and treatment of nasopharyngeal carcinoma in the future.
Methods: Differentially expressed genes were analyzed from the GSE227541 dataset, and functional enrichment analysis was conducted. With mucin 5B, oligomeric mucus/gel-forming as the focus, the correlation between its expression and immune indexes was analyzed by using the TIMER database.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!